(Q36550813)

14 August 2017

Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa (English)

1 reference

14 August 2017

0 references

1 reference

3

Ian Sanne

1 reference

14 August 2017

Elizabeth J. Phillips

1

object named as

Elizabeth Phillips

1 reference

14 August 2017

10

Simon A Mallal

1 reference

14 August 2017

John A Bartlett

2

1 reference

14 August 2017

Michael M Lederman

4

1 reference

14 August 2017

John Hinkle

5

1 reference

14 August 2017

Franck Rousseau

6

1 reference

14 August 2017

David Dunn

7

1 reference

14 August 2017

Rebecca Pavlos

8

1 reference

14 August 2017

Ian James

9

1 reference

14 August 2017

David W Haas

11

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 February 2013

1 reference

Journal of Acquired Immune Deficiency Syndromes

14 August 2017

1 reference

14 August 2017

62

1 reference

14 August 2017

2

1 reference

14 August 2017

e55-7

1 reference

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551216

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551216

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551216

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551216

HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551216

HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551216

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3551216

Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23328091

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HLA-Cw8 primarily associated with hypersensitivity to nevirapine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23328091

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1097/QAI.0B013E31827CA50F

1 reference

14 August 2017

1 reference

14 August 2017

1 reference